Download PDF
Facial Plast Surg 2013; 29(05): 402-410
DOI: 10.1055/s-0033-1353381
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Skin Cancer in Immunosuppressed Patients

Elizabeth A. Gordon Spratt
1   Department of Dermatology, New York University School of Medicine, New York, New York
,
John A. Carucci
1   Department of Dermatology, New York University School of Medicine, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2013 (online)

    Permissions and Reprints

Abstract

Organ transplant recipients suffer from an increased incidence and recurrence rate of nonmelanoma skin cancers. These cancers are often more aggressive than those in the general population, resulting in significant morbidity and mortality. Often times, routine treatment modalities are not adequate and the use of different management strategies is necessary. Treatment modalities, including surgical excision, Mohs micrographic surgery, physically destructive modalities, topical therapy, and photodynamic therapy may be used. Combinations of these therapies may be used in rotation for treatment of extensive field disease. Chemoprophylaxis with oral retinoids and alteration of the immune suppression regimen may be indicated for specific cases. In addition, newly emerging therapies for squamous cell carcinomas including cetuximab and capecitabine may offer heightened control in organ transplant patients with significant cutaneous disease.

Keywords

organ transplant - nonmelanoma skin cancer - treatment - field disease
 

  • References

  • 1 Feuerstein I, Geller AC. Skin cancer education in transplant recipients. Prog Transplant 2008; 18 (4) 232-241 , quiz 242
    PubMedGoogle Scholar
  • 2 Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47 (1) 1-17 , quiz 18–20
    CrossrefPubMedGoogle Scholar
  • 3 Rogers HW, Weinstock MA, Harris AR , et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146 (3) 283-287
    CrossrefPubMedGoogle Scholar
  • 4 Hartevelt MM, Bavinck JN, Kootte AM , et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49 (3) 506-509
    CrossrefPubMedGoogle Scholar
  • 5 Jensen P, Hansen S, Møller B , et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40 (2 Pt 1) 177-186
    CrossrefPubMedGoogle Scholar
  • 6 Sheil AG, Disney AP, Mathew TH , et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25 (1 Pt 2) 1383-1384
    PubMedGoogle Scholar
  • 7 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348 (17) 1681-1691
    CrossrefPubMedGoogle Scholar
  • 8 Carucci JA. Cutaneous oncology in organ transplant recipients: meeting the challenge of squamous cell carcinoma. J Invest Dermatol 2004; 123 (5) 809-816
    CrossrefPubMedGoogle Scholar
  • 9 Jemec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003; 75 (3) 253-257
    CrossrefPubMedGoogle Scholar
  • 10 Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65 (2) 253-261 , quiz 262
    CrossrefPubMedGoogle Scholar
  • 11 Winkelhorst JT, Brokelman WJ, Tiggeler RG , et al. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27 (4) 409-413
    CrossrefPubMedGoogle Scholar
  • 12 Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26 (6) 976-990
    CrossrefPubMedGoogle Scholar
  • 13 Osterlind A, Hjalgrim H, Kulinsky B , et al. Skin cancer as a cause of death in Denmark. Br J Dermatol 1991; 125 (6) 580-582
    CrossrefPubMedGoogle Scholar
  • 14 Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993; 7 (2) 431-445
    PubMedGoogle Scholar
  • 15 Stasko T, Brown MD, Carucci JA , et al; International Transplant-Skin Cancer Collaborative; European Skin Care in Organ Transplant Patients Network. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30 (4 Pt 2) 642-650
    CrossrefPubMedGoogle Scholar
  • 16 Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin 2011; 29 (2) 161-174, vii vii.
    CrossrefPubMedGoogle Scholar
  • 17 Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65 (2) 263-279 , quiz 280
    CrossrefPubMedGoogle Scholar
  • 18 de Graaf YG, Basdew VR, van Zwan-Kralt N , et al. The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation. Br J Dermatol 2006; 154 (3) 493-497
    CrossrefPubMedGoogle Scholar
  • 19 Ulrich C, Busch JO, Meyer T , et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006; 155 (2) 451-454
    CrossrefPubMedGoogle Scholar
  • 20 Brown VL, Atkins CL, Ghali L , et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141 (8) 985-993
    CrossrefPubMedGoogle Scholar
  • 21 Perrett CM, McGregor JM, Warwick J , et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156 (2) 320-328
    CrossrefPubMedGoogle Scholar
  • 22 Mikolajewska P, Iani V, Juzeniene A , et al. Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema. Br J Dermatol 2009; 161 (5) 1173-1179
    CrossrefPubMedGoogle Scholar
  • 23 Britton JE, Goulden V, Stables G , et al. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. Br J Dermatol 2005; 153 (4) 780-784
    CrossrefPubMedGoogle Scholar
  • 24 Leibovitch I, Huilgol SC, Selva D , et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53 (2) 253-260
    CrossrefPubMedGoogle Scholar
  • 25 Veness MJ, Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol 2007; 51 (1) 12-20
    CrossrefPubMedGoogle Scholar
  • 26 Altinyollar H, Berberoğlu U, Celen O. Lymphatic mapping and sentinel lymph node biopsy in squamous cell carcinoma of the lower lip. Eur J Surg Oncol 2002; 28 (1) 72-74
    CrossrefPubMedGoogle Scholar
  • 27 Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer 2006; 106 (11) 2389-2396
    CrossrefPubMedGoogle Scholar
  • 28 Hardin J, Mydlarski PR. Systemic retinoids: chemoprevention of skin cancer in transplant recipients. Skin Therapy Lett 2010; 15 (7) 1-4
    PubMedGoogle Scholar
  • 29 George R, Weightman W, Russ GR , et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43 (4) 269-273
    CrossrefPubMedGoogle Scholar
  • 30 de Sévaux RG, Smit JV, de Jong EM , et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49 (3) 407-412
    CrossrefPubMedGoogle Scholar
  • 31 Euvrard S, Kanitakis J, Decullier E , et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81 (8) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 32 EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant 2002; 17 (Suppl. 04) 31-36
    PubMedGoogle Scholar
  • 33 Neuburg M. Transplant-associated skin cancer: role of reducing immunosuppression. J Natl Compr Canc Netw 2007; 5 (5) 541-549
    PubMedGoogle Scholar
  • 34 Moloney FJ, Kelly PO, Kay EW , et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004; 30 (4 Pt 2) 674-678
    CrossrefPubMedGoogle Scholar
  • 35 Leblanc Jr KG, Hughes MP, Sheehan DJ. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2011; 37 (6) 744-749
    CrossrefPubMedGoogle Scholar
  • 36 Salgo R, Gossmann J, Schöfer H , et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10 (6) 1385-1393
    CrossrefPubMedGoogle Scholar
  • 37 Euvrard S, Morelon E, Rostaing L , et al; TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367 (4) 329-339
    CrossrefPubMedGoogle Scholar
  • 38 Fulton Jr JE, Carter DM, Hurley HJ. Treatment of Bowen's disease with topical 5-fluorouracil under occlusion. Arch Dermatol 1968; 97 (2) 178-180
    CrossrefPubMedGoogle Scholar
  • 39 Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985; 121 (2) 207-213
    CrossrefPubMedGoogle Scholar
  • 40 van Zuuren EJ, Posma AN, Scholtens RE , et al. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994; 31 (5 Pt 1) 760-764
    CrossrefPubMedGoogle Scholar
  • 41 Carucci JA, Martinez JC, Zeitouni NC , et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg 2004; 30 (4 Pt 2) 651-655
    CrossrefPubMedGoogle Scholar
  • 42 Martinez JC, Otley CC, Stasko T , et al; Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139 (3) 301-306
    CrossrefPubMedGoogle Scholar
  • 43 Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection?. Dermatol Surg 2007; 33 (4) 410-420
    CrossrefPubMedGoogle Scholar
  • 44 Martinez JC, Otley CC, Okuno SH , et al. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg 2004; 30 (4 Pt 2) 679-686
    CrossrefPubMedGoogle Scholar
  • 45 Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36 (12) 2069-2074
    CrossrefPubMedGoogle Scholar
  • 46 Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007; 143 (7) 889-892
    CrossrefPubMedGoogle Scholar
  • 47 Caron J, Dereure O, Kerob D , et al. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol 2009; 161 (3) 702-703
    PubMedGoogle Scholar
  • 48 Rubió Casadevall J, Graña-Suárez B, Hernandez-Yagüe X , et al. Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab. Eur J Dermatol 2009; 19 (2) 163-165
    PubMedGoogle Scholar
  • 49 Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther 2012; 12 (7) 949-956
    CrossrefPubMedGoogle Scholar
  • 50 Kalapurakal SJ, Malone J, Robbins KT , et al. Cetuximab in refractory skin cancer treatment. J Cancer 2012; 3: 257-261
    CrossrefPubMedGoogle Scholar
  • 51 Maubec E, Petrow P, Scheer-Senyarich I , et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29 (25) 3419-3426
    CrossrefPubMedGoogle Scholar
  • 52 Bonner JA, Harari PM, Giralt J , et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354 (6) 567-578
    CrossrefPubMedGoogle Scholar
  • 53 Leard LE, Cho BK, Jones KD , et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007; 26 (12) 1340-1344
    CrossrefPubMedGoogle Scholar
  • 54 Beach DF, Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol 2011; 29 (14) e397-e401
    CrossrefPubMedGoogle Scholar
  • 55 Jegannathen A, Mais K, Sykes A , et al. Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. Clin Oncol (R Coll Radiol) 2011; 23 (2) 149-158
    CrossrefPubMedGoogle Scholar
  • 56 Wollina U, Hansel G, Koch A , et al. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005; 131 (5) 300-304
    CrossrefPubMedGoogle Scholar
  • 57 Endrizzi BT, Lee PK. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg 2009; 35 (10) 1567-1572
    CrossrefPubMedGoogle Scholar
  • 58 Jirakulaporn T, Endrizzi B, Lindgren B , et al. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011; 25 (4) 541-548
    CrossrefPubMedGoogle Scholar